Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase. The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory. Reduction of the 16,17-double bond to give 17 beta-pyridyl derivatives diminished potency with 3-pyridyl substitution (3-->27; IC50 for lyase, 2.9-->23 nM) but increased it with a 4-pyridyl substituent present (10-->28; IC50 1 microM-->53 nM). In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3 beta-ol (3, Kiapp < 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM). Thus compounds having variously aromatic ring A (18), saturated rings A/B (21, 22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range. The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [11]
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Palladium-catalyzed cross-coupling reaction of organoboron compounds with organic triflates
Ohe, T., Miyaura, N., & Suzuki, A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00060a041 · Cited by 321
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS
Goldstein, A. (1944) · Journal of General Physiology · doi:10.1085/jgp.27.6.529 · Cited by 181
KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER
Trachtenberg, J., & Pont, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92909-x · Cited by 162
Steroid Hormones: A Practical Approach
(1989) · Tumori Journal · doi:10.1177/030089168907500230 · Cited by 100
Labrie, F., Belanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Is there a case for P-450 inhibitors in cancer treatment?
Wauwe, J. P. V., & Janssen, P. A. J. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a001 · Cited by 88
FORTI, G., SALERNO, R., MONETI, G., ZOPPI, S., FIORELLI, G., MARINONI, T., NATALI, A., COSTANTINI, A., SERIO, M., MARTINI, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Cited by
Items 101–200 of 403
Savić, M. P., Ajduković, J. J., Plavša, J. J., Bekić, S. S., Ćelić, A. S., Klisurić, O. R., Jakimov, D., Petri, E. T., & Djurendić, E. A. (2018) · MedChemComm · doi:10.1039/c8md00077h · Cited by 49
Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives
Deng, G., Zhou, B., Wang, J., Chen, Z., Gong, L., Gong, Y., Wu, D., Li, Y., Zhang, H., & Yang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.025 · Cited by 44
Inhibitors of enzymes of androgen biosynthesis: cytochrome P45017α and 5α-steroid reductase
Jarman, M., Smith, H. J., Nicholls, P. J., & Simons, C. (1998) · Natural Product Reports · doi:10.1039/a815495y · Cited by 49
Self-citationNakka, M., Agoulnik, I. U., & Weigel, N. L. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.12.012 · Cited by 49
Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
Kim, W. K., & Ryan, C. J. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0188-2 · Cited by 45
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors
Moreira, V. M., Vasaitis, T. S., Njar, V. C. O., & Salvador, J. A. R. (2007) · Steroids · doi:10.1016/j.steroids.2007.08.004 · Cited by 51
Inhibition of Cytochromes P450: Existing and New Promising Therapeutic Targets
Schuster, I., & Bernhardt, R. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701498455 · Cited by 48
Germain, L., Lafront, C., Paquette, V., Neveu, B., Paquette, J., Pouliot, F., & Audet‐Walsh, É. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00726-1 · Cited by 52
Inhibition of steroid C17(20) lyase with C-17-heteroaryl steroids
Burkhart, J. P., Gates, C. A., Laughlin, M. E., Resvick, R. J., & Peet, N. P. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(96)00135-6 · Cited by 43
Shin, J., Moon, H. J., Kim, T. S., Kang, I. H., Ki, H. Y., Choi, K. S., & Han, S. Y. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0080-6 · Cited by 43
Potter, G. A., Hardcastle, I. R., & Jarman, M. (1997) · Organic Preparations and Procedures International · doi:10.1080/00304949709355175 · Cited by 41
Self-citationNjar, V. C. O., Hector, M., & Hartmann, R. W. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(96)00138-1 · Cited by 41
C17,20-Lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors
Matsunaga, N., Kaku, T., Itoh, F., Tanaka, T., Hara, T., Miki, H., Iwasaki, M., Aono, T., Yamaoka, M., Kusaka, M., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.02.007 · Cited by 41
Hu, Q., Negri, M., Ölgen, S., & Hartmann, R. W. (2010) · ChemMedChem · doi:10.1002/cmdc.201000065 · Cited by 40
Pharmaceutical drug development: high drug prices and the hidden role of public funding
Annett, S. (2020) · Biologia Futura · doi:10.1007/s42977-020-00025-5 · Cited by 51
Li, J.-S., Li, Y., Son, C., & Brodie, A. M. H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960245f · Cited by 40
Maity, S. N., Titus, M. A., Gyftaki, R., Wu, G., Lu, J.-F., Ramachandran, S., Li-Ning-Tapia, E. M., Logothetis, C. J., Araujo, J. C., & Efstathiou, E. (2016) · Scientific Reports · doi:10.1038/srep35354 · Cited by 42
P450 Enzymes in Steroid Processing
Auchus, R. J., & Miller, W. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_12 · Cited by 44
Logothetis, C. J., Efstathiou, E., Manuguid, F., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3516 · Cited by 40
Abiraterone acetate: redefining hormone treatment for advanced prostate cancer
Pezaro, C. J., Mukherji, D., & Bono, J. S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.012 · Cited by 43
Donato, M. D., Giovannelli, P., Migliaccio, A., & Castoria, G. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01008-4 · Cited by 42
Njar, V. C. O., Klus, G. T., & Brodie, A. M. H. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00512-4 · Cited by 38
Efficient synthesis of isoquinolines and pyridines via copper(i)-catalyzed multi-component reaction
Shekarrao, K., Kaishap, P. P., Gogoi, S., & Boruah, R. C. (2014) · RSC Advances · doi:10.1039/c3ra46722h · Cited by 38
1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents
Khatik, G. L., Kaur, J., Kumar, V., Tikoo, K., & Nair, V. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.059 · Cited by 38
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
Barrie, S. E., Haynes, B. P., Potter, G. A., Chan, F. C. Y., Goddard, P. M., Dowsett, M., & Jarman, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00225-7 · Cited by 37
Self-citationFizazi, K. S., Chi, K. N., Bono, J. S. D., Gomella, L. G., Miller, K., Rathkopf, D. E., Ryan, C. J., Scher, H. I., Shore, N. D., Porre, P. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.035 · Cited by 40
Fehl, C., Vogt, C. D., Yadav, R., Li, K., Scott, E. E., & Aubé, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00419 · Cited by 38
Drug-induced endocrine blood pressure elevation
Beck, K. R., Thompson, G. R., & Odermatt, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104311 · Cited by 42
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Wadosky, K. M., & Koochekpour, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14090 · Cited by 44
Gurav, S. D., Punde, R., Farooqui, J., Zainuddin, M., Rajagopal, S., & Mullangi, R. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1726 · Cited by 36
Synthesis of steroids with nitrogen-containing substituents in ring D (Review)
Stulov, S., & Misharin, A. Y. (2013) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-013-1158-8 · Cited by 44
Kim, W. K., Zhang, L., Wilton, J. H., Fetterly, G. J., Mohler, J. L., WEINBERG, V. K., Morse, A. B., Szmulewitz, R. Z., Friedlander, T. W., Fong, L. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1595 · Cited by 37
Hussain, M., Corn, P. G., Michaelson, M. D., Hammers, H. J., Alumkal, J. J., Ryan, C. J., Bruce, J. Y., Moran, S. E., Lee, S.-Y., Lin, H. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0356 · Cited by 35
Zhao, L., Sun, N., Tian, L., Zhao, S., Sun, B., Sun, Y., & Zhao, D. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.040 · Cited by 36
Wikström, P., Stattin, P., Franck-Lissbrant, I., Damber, J.-E., & Bergh, A. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3 · Cited by 307
Garrido, M., Peng, H.-M., Yoshimoto, F. K., Upadhyay, S. K., Bratoeff, E., & Auchus, R. J. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.013 · Cited by 35
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
Armandari, I., Hamid, A. R. A. H., Verhaegh, G. W. C. T., & Schalken, J. A. (2014) · Prostate International · doi:10.12954/pi.14063 · Cited by 42
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Verma, S., Prajapati, K. S., Kushwaha, P. P., Shuaib, M., Singh, A. K., Kumar, S., & Gupta, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.45 · Cited by 48
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 39
Novel Steroidal Vinyl Fluorides as Inhibitors of Steroid C17(20) Lyase
Burkhart, J. P., Weintraub, P. M., Gates, C. A., Resvick, R. J., Vaz, R. J., Friedrich, D., Angelastro, M. R., Bey, P., & Peet, N. P. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00354-6 · Cited by 33
Shin, J., Moon, H. J., Kang, I. H., Kim, T. S., Kim, I. Y., Park, I. S., Kim, H. S., Jeung, E. B., & Han, S.-Y. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0116-y · Cited by 33
Ling, Y., Li, J.-S., Kato, K., Yang, L., Wang, X., Klus, G. T., Marat, K., Nnane, I. P., & Brodie, A. M. H. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00110-2 · Cited by 33
Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., & Yamaoka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.10.020 · Cited by 34
Alyamani, M., Li, Z., Upadhyay, S. K., Anderson, D. J., Auchus, R. J., & Sharifi, N. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.002 · Cited by 33
Conjugate base catalysed one-pot synthesis of pyrazoles from β-formyl enamides
Saikia, A. K., Barthakur, M. G., Borthakur, M., Saikia, C. J., Bora, U., & Boruah, R. C. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.10.145 · Cited by 31
Effect of Essential Oil Components on the Activity of Steroidogenic Cytochrome P450
Sharma, K., Lanzilotto, A., Yakubu, J., Therkelsen, S., Voegel, C. D., du Toit, T., Jørgensen, F. S., & Pandey, A. V. (2024) · Biomolecules · doi:10.3390/biom14020203 · Cited by 42
Novel drugs targeting the androgen receptor pathway in prostate cancer
Mateo, J., Smith, A. D., Ong, M., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9472-2 · Cited by 34
Novel treatment strategies in congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000256 · Cited by 30
Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs
Romero-Hernández, L. L., Merino‐Montiel, P., Meza‐Reyes, S., Vega-Báez, J. L., López, Ó., Padrón, J. M., & Montiel‐Smith, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.063 · Cited by 30
Sharma, U., Bora, U., Boruah, R. C., & Sandhu, J. S. (2002) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)02049-4 · Cited by 30
Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer
Yang, L. P. H. (2011) · Drugs · doi:10.2165/11208080-000000000-00000 · Cited by 31
Crawford, E. D., Stanton, W. N., & Mandair, D. (2020) · Cancer Management and Research · doi:10.2147/cmar.s227583 · Cited by 29
Kumar, S. V., Rudresha, G., Gurav, S. D., Zainuddin, M., Dewang, P. M., Kethiri, R. R., Rajagopal, S., & Mullangi, R. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2776 · Cited by 30
Monbaliu, J. G., Gonzalez, M., Bernard, A., Jiao, J., Sensenhauser, C., Snoeys, J., Stieltjes, H., Wynant, I., Smit, J. W., & Chien, C. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070672 · Cited by 29
Wang, Q., Han, J., Liang, Z., Geng, X., Du, Y., Zhou, J., Yao, W., & Xu, T. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319426 · Cited by 28
Lewis, S. R., Hedman, C. J., Ziegler, T. E., Ricke, W. A., & Jorgensen, J. S. (2013) · Endocrinology · doi:10.1210/en.2013-1583 · Cited by 28
Barthakur, M. G., Gogoi, S., Dutta, M., & Boruah, R. C. (2009) · Steroids · doi:10.1016/j.steroids.2009.03.006 · Cited by 28
Grigoryev, D. N., Kato, K., Njar, V. C. O., Long, B. J., Ling, Y. Z., Wang, X., Mohler, J. L., & Brodie, A. M. H. (1999) · Analytical Biochemistry · doi:10.1006/abio.1998.2993 · Cited by 28
New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication
Gunter, J. H., Sarkar, P. L., Lubik, A. A., & Nelson, C. C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/834684 · Cited by 31
Novel Therapeutic Strategies for Metastatic Prostate Cancer in the Post-Docetaxel Setting
Sartor, O. A., Michels, R. M., Massard, C., & Bono, J. S. D. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0412 · Cited by 32
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
POUTANEN, M. H., Thulin, M. H., & Härkönen, P. L. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00609-y · Cited by 32
Haider, S. M., Patel, J. S., Poojari, C., & Neidle, S. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.069 · Cited by 27
MARTINS, V., Asad, Y. J., Wilsher, N. E., & Raynaud, F. I. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.06.010 · Cited by 27
Development of a Chemoenzymatic Process for Dehydroepiandrosterone Acetate Synthesis
Fryszkowska, A., Peterson, J. A., Davies, N. L., Dewar, C., Evans, G., Bycroft, M., Triggs, N., Fleming, T., Gorantla, S. S., Hoge, G. S., et al. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00215 · Cited by 27
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 32
Neyra, J. A., Rocha, N. A., Bhargava, R., Vaidya, O. U., Hendricks, A. R., & Rodan, A. R. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0113-6 · Cited by 28
New Opportunities for Targeting the Androgen Receptor in Prostate Cancer
Centenera, M. M., Selth, L. A., Ebrahimie, E., Butler, L. M., & Tilley, W. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030478 · Cited by 30
Zolottsev, V. А., Tkachev, Y. V., Latysheva, А. S., Kostin, V. A., Новиков, Р. А., Timofeev, V. P., Morozevich, G. E., Kuzikov, A. V., Shumyantseva, V. V., & Misharin, A. Y. (2017) · Steroids · doi:10.1016/j.steroids.2017.11.009 · Cited by 25
New Therapeutics to Treat Castrate‐Resistant Prostate Cancer
Acar, Ö., Esen, T., & Lack, N. A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/379641 · Cited by 31
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Hoefer, J., Schwaiger, S., Heidegger, I. M., Matuszczak, B., Schuster, D., et al. (2020) · Cancers · doi:10.3390/cancers12082092 · Cited by 26
Guarna, A., Occhiato, E. G., Machetti, F., & Giacomelli, V. (1999) · The Journal of Organic Chemistry · doi:10.1021/jo990373m · Cited by 24
New treatment developments applied to elderly patients with advanced prostate cancer
Mukherji, D., Pezaro, C. J., Shamseddine, A. I., & Bono, J. S. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.004 · Cited by 25
Houédé, N., Beuzeboc, P., Gourgou, S., Tosi, D., Moise, L., Gravis, G., Delva, R., Fléchon, A., Latorzeff, I., Ferrero, J.-M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1257-2 · Cited by 26
Neighboring group participation
Ondré, D., Woelfling, J., Iványi, Z., Schneider, G., Tóth, I., Szécsi, M., & Julesz, J. (2008) · Steroids · doi:10.1016/j.steroids.2008.06.011 · Cited by 23
Sun, H., Mediwala, S. N., Szafran, A. T., Mancini, M. A., & Marcelli, M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0257-2 · Cited by 23
Microwave promoted one-pot synthesis of novel A-ring fused steroidal dehydropiperazines
Borthakur, M., Barthakur, M. G., & Boruah, R. C. (2008) · Steroids · doi:10.1016/j.steroids.2008.01.005 · Cited by 23
Petrunak, E. M., Bart, A. G., Peng, H., Auchus, R. J., & Scott, E. E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102999 · Cited by 23
Prostate cancer—from steroid transformations to clinical translation
Chang, K., & Sharifi, N. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.175 · Cited by 23
New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone
Latysheva, А. S., Zolottsev, V. А., Veselovsky, A. V., Scherbakov, K. A., Morozevich, G. E., Pokrovsky, V. S., Новиков, Р. А., Timofeev, V. P., Tkachev, Y. V., & Misharin, A. Y. (2019) · Steroids · doi:10.1016/j.steroids.2019.108534 · Cited by 22
Synthesis of steroidal diacyl hydrazines and their 1,3,4-oxadiazole derivatives
Szarka, Z., Skoda‐Földes, R., Horváth, J., Tuba, Z., & Kollár, L. (2002) · Steroids · doi:10.1016/s0039-128x(02)00006-5 · Cited by 22
Izumi, K., Mizokami, A., Namiki, M., Inoue, S., Tanaka, N., Yoshio, Y., Ishibashi, K., Kamiyama, M., Kawai, N., Enokida, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3661-2 · Cited by 22
Šestić, T. L., Ajduković, J. J., Marinović, M., Petri, E. T., & Savić, M. P. (2022) · Steroids · doi:10.1016/j.steroids.2022.109147 · Cited by 21
Han, C. S., Patel, R., & Kim, I. Y. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1041918 · Cited by 20
Harshman, L. C., & Taplin, M. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0050-3 · Cited by 27
Quest for steroidomimetics: Amino acids derived steroidal and nonsteroidal architectures
Shagufta, S., Ahmad, I., & Panda, G. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.054 · Cited by 21
Gogoi, J., Gogoi, P., Bezbaruah, P., & Boruah, R. C. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.10.094 · Cited by 21
Sakai, Y., Fukami, T., Nagaoka, M., Hirosawa, K., Ichida, H., Sato, R., Suzuki, K., Nakano, M., & Nakajima, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119896 · Cited by 21
Kafka, M., Giannini, G., Artamonova, N., Neuwirt, H., Ofner, H., Kramer, G., Bauernhofer, T., Luger, F., Höfner, T., Loidl, W. C., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.12.018 · Cited by 22
Functionalization of Pyridines at the C4 Position via Metalation and Capture
Hsu, H., Kang, S., Chen, C., Sk, M. R., & Thomas, A. A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202424172 · Cited by 20
Szabó, N., Ajduković, J. J., Djurendić, E. A., Sakač, M. N., Ignáth, I., Gardi, J., Mahmoud, G., Klisurić, O. R., Jovanović-Šanta, S., Gaši, K. M. P., et al. (2015) · Acta Biologica Hungarica · doi:10.1556/abiol.66.2015.1.4 · Cited by 20
Novel steroidal pyrimidyl inhibitors of P450 17 (17α-hydroxylase/C17-20-lyase)
Haidar, S., Ehmer, P. B., & Hartmann, R. W. (2001) · Archiv der Pharmazie · doi:10.1002/1521-4184(200112)334:12 · Cited by 20
Michalak, K., Morawiak, M., & Wicha, J. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b03157 · Cited by 20
Emerging Therapies in Castrate-Resistant Prostate Cancer
Zarour, L. R., & Alumkal, J. J. (2010) · Current Urology Reports · doi:10.1007/s11934-010-0104-x · Cited by 25
Steroidogenic cytochrome P450 enzymes as drug target
Kim, C., Jeong, E., Lee, Y.-B., & Kim, D. (2024) · Toxicological Research · doi:10.1007/s43188-024-00237-0 · Cited by 21
Targeting androgen receptor signaling: a historical perspective
Davies, A., & Zoubeidi, A. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0116 · Cited by 19
Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs
Avgeris, I., Pliatsika, D., Nikolaropoulos, S. S., & Fousteris, M. A. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106089 · Cited by 21
The development of abiraterone acetate for castration-resistant prostate cancer
Grist, E., & Attard, G. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.03.021 · Cited by 24
Gravanis, I., Sancho-López, A., Hemmings, R. J., Jiménez, J. C., García‐Carbonero, R., Gallego, I. G., Giménez, E. V., O’Connor, D. J., Giuliani, R., Salmonson, T., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0092 · Cited by 22
Nikonovich, T., Hurski, A. L., Morozevich, G. E., Latysheva, А. S., Sushko, T. A., Strushkevich, N. V., Gilep, A. A., Misharin, A. Y., Zhabinskii, V. N., & Khripach, V. A. (2018) · Steroids · doi:10.1016/j.steroids.2018.08.004 · Cited by 18
Potential Strategies for Increasing Drug-Discovery Productivity
Cumming, J. G., Finlay, M. R. V., Giordanetto, F., Hemmerling, M., Lister, T., Sanganee, H. J., & Waring, M. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.7 · Cited by 20
Metadata
- Authors
- Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-06
- Volume
- 38
- Issue
- 13
- Pages
- 2463-2471
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2027081726
- Cited by
- 379
- References
- 33
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 21 · 2016: 20 · 2015: 21 · 2014: 28 · 2013: 31 · 2012: 28
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- CYP17 inhibitors, steroids, palladium-catalyzed cross-coupling, structure-activity relationship, steroid synthesis, prostate cancer, hormone-dependent prostate cancer, androstenedione, pregnenolone, progesterone
- MeSH terms
- Humans, Male, Magnetic Resonance Spectroscopy, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroids, Structure-Activity Relationship, Testis, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.